Tweet
<img alt="" height="1" width="1" />
Amgen Cytokinetics Heart Drug Fails in Atomic Patient Trial
Businessweek
Amgen Inc. (AMGN:US) and Cytokinetics Inc. (CYTK:US)'s experimental drug omecamtiv mecarbil failed to help people with acute heart failure breathe better in a 613-patient, company-sponsored study. Patients who took the treatment didn't experience any ...
Amgen And Cytokinetics Announce The First Presentation Of Data From Phase 2 ...MarketWatch
Amgen, Cytokinetics Report Mixed Results For Heart Failure DrugTheStreet.com
Amgen, Cytokinetics heart failure drug misses goal in studyReuters UK
all 12 news articles »
More...